Marksans Pharma Limited — Investor Meet, 25-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Marksans Pharma reported operating revenue of INR 682 crores for Q3 FY25, representing a 16.3% year-on-year increase. The U.S. and North American markets drove this growth, with a remarkable 37.1% year-on-year rise to INR 353 crores. Gross profit increased by 22.4% to INR 384 crores, leading to a gross margin expansion of 279 basis points to 56.2%. Profit after tax for the quarter reached an all-time high of INR 105 crores, up 26.6% from INR 83 crores in Q3 FY24. However, EBITDA decreased by 4.3% year-on-year to INR 138.8 crores due to higher employee and freight costs, resulting in an EBITDA margin drop to 20.4%.

2. **Future Outlook and Growth Drivers**: The management indicated optimism, focusing on expanding the business through new product launches and ramping up their recently acquired manufacturing facility to reach a revenue milestone of INR 3,000 crores. They anticipate an improvement in U.K. & European performance as well.

3. **Order Book and Operational Updates**: The acquired manufacturing facility is progressing as expected. With 34 products filed in the U.K., management expects revenue growth and continued capacity expansions are on the agenda to meet the upcoming demand.

4. **Analyst Q&A Insights**:

- **Revenue and Profitability**: Analysts inquired about the EBITDA margin fluctuations, with management clarifying that increased costs stemming from employee hiring and freight issues were significant contributors. They expect margin improvements in the upcoming quarters as these costs stabilize.

- **Market Position**: Questions on competition highlighted increasing performance from U.S. pharmaceutical companies, but management asserted their strategic advantages.

- **Operational Challenges**: Analysts pressed on cost pressures due to fluctuating freight costs and raw material pricing, with responses indicating expected stabilization.

- **Capex and Capital Allocation**: Discussions included future capital spending, primarily focused on optimizing their facilities and potential M&A opportunities.

- **Long-Term Vision**: Management reiterated their ambitious growth targets, emphasizing plans to scale to INR 4,000 crores as a next milestone.

5. **Market or Regulatory Updates**: There were no significant market or regulatory developments reported that directly impacted the company's strategies or forecasts.

6. **Strategic Focus Areas**: The company continues its drive towards innovation and operational efficiency, with a keen focus on leveraging its low-cost manufacturing base in India to sustain competitive advantages, particularly against potential tariff changes.

7. **Investor Insight**: Marksans Pharma's solid financial performance combined with a robust growth strategy may position it favorably for retail investors looking for value, suggesting a “buy” stance based on future growth potential and sound financial health. However, ongoing risks, particularly in operational costs and competitive pressures, warrant cautious monitoring.